259 related articles for article (PubMed ID: 31727847)
21. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.
Mazrooei P; Kron KJ; Zhu Y; Zhou S; Grillo G; Mehdi T; Ahmed M; Severson TM; Guilhamon P; Armstrong NS; Huang V; Yamaguchi TN; Fraser M; van der Kwast T; Boutros PC; He HH; Bergman AM; Bristow RG; Zwart W; Lupien M
Cancer Cell; 2019 Dec; 36(6):674-689.e6. PubMed ID: 31735626
[TBL] [Abstract][Full Text] [Related]
22. The advances in CRISPR technology and 3D genome.
Wang W; Zhang L; Wang X; Zeng Y
Semin Cell Dev Biol; 2019 Jun; 90():54-61. PubMed ID: 30004018
[TBL] [Abstract][Full Text] [Related]
23. Sequential in
Amândio AR; Beccari L; Lopez-Delisle L; Mascrez B; Zakany J; Gitto S; Duboule D
Genes Dev; 2021 Nov; 35(21-22):1490-1509. PubMed ID: 34711654
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional regulation of human DUSP4 gene by cancer-related transcription factors.
Varela T; Conceição N; Laizé V; Cancela ML
J Cell Biochem; 2021 Oct; 122(10):1556-1566. PubMed ID: 34254709
[TBL] [Abstract][Full Text] [Related]
25. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
26. Systematic functional interrogation of human pseudogenes using CRISPRi.
Sun M; Wang Y; Zheng C; Wei Y; Hou J; Zhang P; He W; Lv X; Ding Y; Liang H; Hon CC; Chen X; Xu H; Chen Y
Genome Biol; 2021 Aug; 22(1):240. PubMed ID: 34425866
[TBL] [Abstract][Full Text] [Related]
27. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
28. Active enhancers strengthen insulation by RNA-mediated CTCF binding at chromatin domain boundaries.
Islam Z; Saravanan B; Walavalkar K; Farooq U; Singh AK; Radhakrishnan S; Thakur J; Pandit A; Henikoff S; Notani D
Genome Res; 2023 Jan; 33(1):1-17. PubMed ID: 36650052
[TBL] [Abstract][Full Text] [Related]
29. Facultative CTCF sites moderate mammary super-enhancer activity and regulate juxtaposed gene in non-mammary cells.
Willi M; Yoo KH; Reinisch F; Kuhns TM; Lee HK; Wang C; Hennighausen L
Nat Commun; 2017 Jul; 8():16069. PubMed ID: 28714474
[TBL] [Abstract][Full Text] [Related]
30. Unique ERalpha cistromes control cell type-specific gene regulation.
Krum SA; Miranda-Carboni GA; Lupien M; Eeckhoute J; Carroll JS; Brown M
Mol Endocrinol; 2008 Nov; 22(11):2393-406. PubMed ID: 18818283
[TBL] [Abstract][Full Text] [Related]
31. Functional assessment of CTCF sites at cytokine-sensing mammary enhancers using CRISPR/Cas9 gene editing in mice.
Lee HK; Willi M; Wang C; Yang CM; Smith HE; Liu C; Hennighausen L
Nucleic Acids Res; 2017 May; 45(8):4606-4618. PubMed ID: 28334928
[TBL] [Abstract][Full Text] [Related]
32. The structural and functional roles of CTCF in the regulation of cell type-specific and human disease-associated super-enhancers.
Shin HY
Genes Genomics; 2019 Mar; 41(3):257-265. PubMed ID: 30456521
[TBL] [Abstract][Full Text] [Related]
33. FOXA1 defines cancer cell specificity.
Zhang G; Zhao Y; Liu Y; Kao LP; Wang X; Skerry B; Li Z
Sci Adv; 2016 Mar; 2(3):e1501473. PubMed ID: 27034986
[TBL] [Abstract][Full Text] [Related]
34. CTCF loss mediates unique DNA hypermethylation landscapes in human cancers.
Damaschke NA; Gawdzik J; Avilla M; Yang B; Svaren J; Roopra A; Luo JH; Yu YP; Keles S; Jarrard DF
Clin Epigenetics; 2020 Jun; 12(1):80. PubMed ID: 32503656
[TBL] [Abstract][Full Text] [Related]
35. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Klann TS; Black JB; Chellappan M; Safi A; Song L; Hilton IB; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2017 Jun; 35(6):561-568. PubMed ID: 28369033
[TBL] [Abstract][Full Text] [Related]
36. Disruption of a -35 kb Enhancer Impairs CTCF Binding and
Liu Q; Thoms JAI; Nunez AC; Huang Y; Knezevic K; Packham D; Poulos RC; Williams R; Beck D; Hawkins NJ; Ward RL; Wong JWH; Hesson LB; Sloane MA; Pimanda JE
Clin Cancer Res; 2018 Sep; 24(18):4602-4611. PubMed ID: 29898989
[No Abstract] [Full Text] [Related]
37. Functional roles of CTCF in breast cancer.
Oh S; Oh C; Yoo KH
BMB Rep; 2017 Sep; 50(9):445-453. PubMed ID: 28648147
[TBL] [Abstract][Full Text] [Related]
38. MCF-7 as a Model for Functional Analysis of Breast Cancer Risk Variants.
Booms A; Coetzee GA; Pierce SE
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1735-1745. PubMed ID: 31292138
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers.
Sérandour AA; Avner S; Percevault F; Demay F; Bizot M; Lucchetti-Miganeh C; Barloy-Hubler F; Brown M; Lupien M; Métivier R; Salbert G; Eeckhoute J
Genome Res; 2011 Apr; 21(4):555-65. PubMed ID: 21233399
[TBL] [Abstract][Full Text] [Related]
40. CTCF-Mediated Enhancer-Promoter Interaction Is a Critical Regulator of Cell-to-Cell Variation of Gene Expression.
Ren G; Jin W; Cui K; Rodrigez J; Hu G; Zhang Z; Larson DR; Zhao K
Mol Cell; 2017 Sep; 67(6):1049-1058.e6. PubMed ID: 28938092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
